1. Home
  2. Directory
  3. Vermont
  4. Rutland
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1245331321

DR. JOHN GAVIN COTTER M.D.
Prescription History 1245331321
Internal Medicine - Infectious Disease in Rutland, VT

NPI Status: Active since September 25, 2006

Contact Information

69 ALLEN ST STE 8
RUTLAND, VT
ZIP 05701
Phone: (802) 772-7169
Fax: (802) 772-7215

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOHN GAVIN COTTER M.D., an active Infectious Disease specialist practicing in Rutland, VT. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 90 documented patient claims. Among these therapy options, the most frequently utilized medication is Cephalexin, which accounts for 29 claims alone.

Medication Index

Cefadroxil

Generic Formulation: CefadroxilSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.0
Days Supply 487
VT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.4
Peer Average Days Supply326
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $611.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$50.98

State Avg Cost Per Claim

$14.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cephalexin

Generic Formulation: CephalexinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 29
30-Day Fills 40.0
Days Supply 1,012
VT State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply307
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $984.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.95

State Avg Cost Per Claim

$9.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 430
VT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply280
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $838.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$59.92

State Avg Cost Per Claim

$24.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ertapenem

Generic Formulation: Ertapenem SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 175
VT State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply189
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,009.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$956.92

State Avg Cost Per Claim

$712.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Therapeutic Applications

Ertapenem is used to prevent and treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 13.0
Days Supply 350
VT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply360
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.21

State Avg Cost Per Claim

$6.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOHN GAVIN COTTER M.D. provides transparency into local medical care patterns within Rutland, VT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.